LDI has sold UltiMed to Levine Leichtman Capital Partners
UltiMed, Inc., a portfolio company of LDI, Ltd., has been sold to an investment vehicle sub-managed by Levine Leichtman Capital Partners, LLC.
UltiMed’s insulin pen needles, syringes and complementary products are critical offerings for diabetes patients who need daily insulin injections and for companion animals who increasingly suffer from this life-threatening disease. UltiMed’s proprietary “dispense and dispose” solutions provide diabetes patients a safe and convenient way to store used sharps following injection.
Levine Leichtman Capital Partners is a private equity and venture capital firm specializing in acquisitions, buyouts, recapitalizations, refinancing, balance sheet restructuring, growth financing, structured equity, distressed debt, leveraged loan and mezzanine investments in the middle market.
LDI, Ltd. is a private equity firm specializing in investing in acquisitions and add-on acquisitions. It is a family office based in Indianapolis, IN, with more than a century of experience funding and operating high-potential, middle-market companies.
One of Oaklins’ teams in the USA served as the exclusive financial advisor to UltiMed, Inc., a portfolio company of LDI, Ltd., in this transaction.



John Martin
VP Corporate Development, LDI, Ltd.
Talk to the deal team

Michael S. Goldman
Managing Director
New York, United StatesOaklins TM Capital


James McLaren
Managing Director
New York, United StatesOaklins TM Capital

Related deals
Groupe Nature acquires Winco
Groupe Nature has signed an agreement with Nicolas Watine, founder and CEO of Winco, to acquire his stake in the comany. It specializes in the distribution of health and cosmetic products in parapharmacies affiliated to supermarket chains. This acquisition strengthens Groupe Nature’s position as a multi-channel specialist in the distribution of organic health products.
Learn moreCamelia pharmacy chain has been acquired by Medigate Management UAB
CGP Management UAB has sold the Camelia pharmacy chain (UAB Nemuno vaistinė and subsidiaries) to Medigate Management UAB.
Learn moreShield Therapeutics has raised funds
Shield Therapeutics Plc has completed a placing, subscription and open offer. The primary use of the funds is to launch Accrufer® in the USA.
Learn more